Gilead Sciences
- GILD
- NASDAQ
- Consumer Products
- Latest 55.48
- Currency US$
- Change -0.45
- Percent Change -0.805 %
- Volume 10,769,704
- Thu May 23, 2013 4:00 PM EDT NASDAQ data delayed 15 minutes.
The Globe and Mail
- Open 54.89
- Previous Close 55.93
- High 56.06
- Low 54.16
- Bidx0 --
- Askx0 --
- 52-week High -- 58.065
- 52-week Low -- 24.12
- Beta 1.532
- Market Cap 84,550.97M
- EPS 1.79
- P/E 30.99
- Forward P/E 20.101
- PEG 1.13
- Annual Dividend --
- Yield --
News
- Four biotech stocks that outperform the market
- Analysis: Drugmakers face more scrutiny of discordant U.S. prices
- Many in U.S. don't get proper testing for hepatitis C- CDC
- US STOCKS-Dow, S&P 500 close at record levels after jobs report
- US STOCKS-Dow, S&P 500 surge to records after U.S. payrolls report
- European Medicines Agency Validates Gilead's Marketing Application for Sofosbuvir for the Treatment of Hepatitis C
- Gilead Sciences to Present at the 2013 UBS Global Healthcare Conference on Monday, May 20
- Gilead Announces Response Data from Phase 2 Study of Idelalisib for Previously Untreated Chronic Lymphocytic Leukemia
- Gilead Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15
- Gilead Sciences Announces First Quarter 2013 Financial Results
Financials & Calendars
- Sales $9,951,710,000
- Earnings $2,871,800,000
- Return on Equity 28.80%
- Cash Flow --
- Cash $1,863,970,000
- Current Ratio 1.55
12 months ended Mar 31, 2013.
Trailing 12 month results shown above.
All data is in U.S. dollars.
- Assets $22,211,670,000
- Liabilities $11,819,200,000
- Liabilities-to-Equity Ratio 1.14
Price Ratios
- Price to Sales 8.50
- Price to Book 8.14
- Price to Cash Flow n/a
Event Calendar
| Event | Last | Next | ||
|---|---|---|---|---|
| Earnings | May 2 | $0.47 | Jul 25 | $0.47 |
| Surprises | May 2 | -4.26% | n/a | n/a |
| Dividends | n/a | n/a | n/a | n/a |
| Splits | Jan 28 | 2:1 | n/a | n/a |
12 months ended May 23, 2013.
A look at major corporate events and financial announcements that are coming up.
Company Information
About the Company
Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.
Officers
- JOHNC. MARTIN Chairman and C.E.O.
- Robin L. Washington Sr. V.P. and C.F.O.
- Company Type: n/a
- Company Status: n/a
- Full-time Employees: n/a
-
Incorporation:
United States,
n/a -
Top 1000 Ranking:
Profit: n/a
Revenue: n/a
Assets: n/a
Head Office
333 LAKESIDE DRFOSTER CITY, CA
94404
Phone: 6505743000
Fax: (650)-5789264
Ideas & Discussion
Live Discussion of GILD on StockTwits